From Concept to Cure: The Journey of a New Drug and Its Cost Impact

In this episode of Pharmland, co-hosts Bradley Nelson and Tom Davies explore the long and often arduous journey of drug development – from early clinical trials to U.S. Food and Drug Administration (FDA) approval and beyond. Learn more about how pharmaceutical companies decide which drugs to pursue, why only 10% of potential therapeutic agents make it to market as a new drug, and how that impacts the price of a drug and therefore, pharmacy plans. Plus, Bradley and Tom explore the history of FDA regulations, the complexities of clinical trials, and the controversial strategies manufacturers use to extend patents, delay generics, and protect market dominance – all of which shape today’s pharmaceutical landscape. Hosts: Bradley Nelson, PharmD, Vice President, Clinical Services Tom Davies, PharmD, Vice President, Clinical Products